Role of Next Generation Vaccines in Immunotherapeutics
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "DNA and mRNA Vaccines".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 139
Special Issue Editor
Special Issue Information
Dear Colleagues,
Vaccines have been instrumental in combating diseases, and next-generation vaccines represent a transformative leap forward in preventing infections and advancing immunotherapeutics. These innovative vaccines offer new approaches to treating and preventing various diseases. Next-generation vaccines encompass nucleic acid vaccines (DNA and RNA), viral vector vaccines, protein subunit vaccines, and recombinant vector vaccines. They offer several advantages over traditional vaccines, such as rapid development, stability, and the ability to elicit specific immune responses. Nucleic acid vaccines, particularly mRNA vaccines, gained global attention during the COVID-19 pandemic for their rapid development and high efficacy. Viral vector and protein subunit vaccines are also being explored for their potential to develop targeted and less reactive vaccines. Next-generation vaccines also show promise in treating chronic diseases, cancers, and autoimmune conditions. They can target specific tumor antigens in cancer immunotherapy and modulate immune responses in autoimmune diseases and allergies. We invite you to contribute a research or review article linking different components of the virus or vaccine to immune responses and clinical or preclinical data.
We look forward to receiving your contributions.
Dr. Swayam Prakash
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapeutics
- vaccines
- nucleic acid vaccines
- viral vector and protein subunit vaccines
- cancer vaccines
- autoimmune diseases and allergies
- COVID-19
- clinical trials
- pre-clinical trials
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
